Our People

Contact Information

Email

patdl@nus.edu.sg

Telephone

+65 83451790

Research Themes

  • HAEMATOLYMPHOID MALIGNANCY

Other Information

ORCID

orcid.org/0000-0003-0022-1551

 

 

Ding Lingwen

RESEARCH ASSISTANT PROFESSOR, NUS
PRINCIPAL INVESTIGATOR, Nanomedicine Translational Research Programme (NanoMed TRP), NUS

RESEARCH FOCUS

  • Developing innovative therapeutic approaches to overcome resistance to cancer immunotherapy
  • Identifying genetic and epigenetic abnormalities in cancers and pre-cancers

BIOGRAPHY

The research interests of Dr. Ding Lingwen focus on two critical areas in cancer research: developing innovative therapeutic approaches to overcome resistance to cancer immunotherapy; and identifying genetic and epigenetic abnormalities in cancers and pre-cancers. He has authored 68 manuscripts in international journals, over half of them were published in journals with impact factor >10. He also served as an invited ad hoc reviewer and reviewed over 430 manuscripts for 124 international journals. Over the past two years, he has successfully secured more than 2.2 million SGD in research funding as the Principal Investigator (PI), and 3.5 million SGD as Co-Investigator and Collaborator. He also contributes as a Team Principal Investigator to a large CRP (Competitive Research Programme) grant from NRF. He was the recipient of the prestigious Lee Kuan Yew Postdoctoral Fellowship and the Year 2021 Gilead Research Scholars Award (Hematology and Oncology).

Group Members

  • Dr. Ran Xuebin (Research Fellow)
  • Dr. Xu Jingru (Research Fellow)
  • Dr. Luo Shanshan (Visiting Research Fellow)
  • Miss. Lai Siaw Wei (Research Assistant)
  • Miss. Li Xin (Research Assistant)
  • Miss. Siti Nur Mahirah Binte Waled (Research Assistant)
  • Miss. Zhang Qing (NUS PhD student)
  • Miss. Oon Min Hui (NUS PhD student)
  • Mr. Guo Junchen (Visiting Medical student)
Tan Soo Yong-right

Recent Publications

Targeting RNA exonuclease XRN1 potentiates efficacy of cancer immunotherapy. Xue-Bin Ran, Ling-Wen Ding (Co-Corresponding author), Qiao-Yang Sun, et al. Cancer Research 2023 Mar 15;83(6):922-938.

RNA-binding protein ZFP36L1 suppresses hypoxia and cell cycle signaling. Xin-Yi Loh, Qiao-Yang Sun, Ling-Wen Ding (Corresponding author), et al. Cancer Research 2020; 80 (2), 219-233.

LNK suppresses interferon signaling in melanoma. Ling-Wen Ding, Qiao-Yang Sun, Jarem J Edwards, et al. Nature Communications 2019; 10(1):2230.

SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells. Qiao-Yang Sun, Ling‐Wen Ding (Corresponding author), Kara Johnson, et al. Oncogene 2019; 38(34):6196-6210.

Mutational and transcriptomic profiling of acute leukemia of ambiguous lineage reveals obscure but clinically important lineage bias. Zhen-Tang Lao, Ling‐Wen Ding (Corresponding author), Omer An, et al. Haematologica 2019; 104(5):e200-e203.

The MYC/BMI1 axis is essential for SETDB1‐mediated breast tumorigenesis. Jin‐Fen Xiao, Qiao‐Yang Sun, Ling‐Wen Ding (Corresponding author), et al. The Journal of Pathology 2018; 246 (1), 89-102.

Mutational landscape of pediatric acute lymphoblastic leukemia. Ling-Wen Ding, Qiao-Yang Sun, Kar-Tong Tan, et al. Cancer Research 2017; 15;77(2):390-400.

Mutational profiling of acute lymphoblastic leukemia with testicular relapse. Ling-Wen Ding, Qiao-Yang Sun, Anand Mayakonda, et al. Journal of Hematology & Oncology 2017; 2; 10(1):65-69.

Mutational profiling of a MonoMAC syndrome family with GATA2 deficiency. Ling-Wen Ding, T Ikezoe, KT Tan, et al. Leukemia 2017; 31(1): 244–245.

Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD). Qiao-Yang Sun, Ling-Wen Ding (Corresponding author), Kar-Tong Tan, et al. Leukemia 2017;31(1):1-10.

Scroll to Top